Kornimate/medical-research-clean huggingface dataset:
symptomatic carotid outcomes registry

Conditions: Carotid Stenosis; Ischemic Stroke; Transient Ischemic Attack

Summary: the purpose of this study is to build upon trials done over 30 years ago, which did not include statins, new antiplatelet agents, and newer antihypertensive medications. since the landmark trials (nascet, ecst), there have been new developments in medical stroke prevention, which creates a gap in knowledge. the aim of this study is to evaluate that clinical care with intensive medical therapy (imt) alone, the one year stroke rate in patients with symptomatic carotid stenosis and low risk clinical features will be \<5%.

this study will only be evaluating clinical care and no interventions will be done specifically for this research. * informed consent from patient or legally authorized representative. * participant survey/questionnaire completion at baseline, 6 and 12 months after enrollment * all data collected will be entered into a secure research data registry created for this study.

Eligibility criteria:
inclusion criteria: * age ≥40 years plus stroke or tia ipsilateral to 50-99% ica stenosis in addition, patients must have at least one clinical or radiologic marker of reduced stroke risk clinical reduced stroke risk: 1. retinal ischemia only (amaurosis fugax, branch retinal artery occlusion (brao), central retinal artery occlusion (crao) 2. female sex 3. most recent stroke or tia \>1 week ago radiologic reduced stroke risk: 1. transcranial doppler (tcd) study demonstrating lack of microembolic signals 2. cross-sectional mri plaque imaging demonstrating absence of intraplaque hemorrhage 3. for patients with tia: brain mri shows no dwi lesion exclusion criteria: atrial fibrillation or other high-risk sources of cardiac embolism unless it is device detected af only or duration \<6 minutes alcohol and substance abuse within the prior 24 months clinically significant bleeding diathesis (platelet count \ 14 seconds) clear indication for therapeutic anticoagulation (for example, dvt or pulmonary embolism within past 3 months) left ventricular ejection fraction \<20% known allergy or intolerance to aspirin or clopidogrel life expectancy less than 12 months moderate/severe dementia (mini-mental or moca score \<22 modified rankin score of \>4 nonatherosclerotic cause of carotid stenosis most recent symptomatic event \>180 days from the time of enrollment -
opt-in vs. opt-out for breast cancer screening

Conditions: Breast Cancer

Summary: this is a randomized controlled trial that will evaluate the effectiveness two different outreach strategies for a population-based breast cancer screening program at the va puget sound among average risk female veterans who are due for breast cancer screening.

this is a prospective, randomized controlled trial that will evaluate the effectiveness of two different outreach strategies in improving adherence to breast cancer screening via mammography. average risk female veterans who are due for breast cancer screening (defined as aged 45-75 with no previous history of bilateral mastectomy, not under hospice care, and alive at the time of screening) will be identified through administrative data. veterans eligible for enrollment into the trial will be randomized in a 1:1 allocation using permuted block randomization (with random block sizes of 2 and 4) to the following interventions: arm 1: automated phone opt-in message intervention type: audiocare message requiring veteran to confirm that they would like to participate in screening and have consult sent arm 2: opt-out scheduling intervention type: consult automatically sent and veteran called to schedule screening randomization will be stratified within arms by prior screening status (prior screener vs. never screener). the study's primary outcome of interest is screening completion at 100 days post randomization. the study's secondary outcome of interest is screening scheduling at 100 days post randomization. subgroup analysis aim 1 will explore whether the differences in breast cancer screening completion between investigational groups varies according to the veterans' race/ethnicity. subgroup analysis aim 2 will explore whether the differences in breast cancer screening scheduling between investigational groups varies according to the veterans' race/ethnicity. enrollment in the trial will occur between march 1, 2022 and august 31, 2022.

Eligibility criteria:
inclusion criteria: * female veterans aged 45-75 * assigned to a primary care provider at the va puget sound as of january 1, 2022 with at least 1 year of prior data available * due for breast cancer screening (have not had a mammogram in the last 12 months) exclusion criteria: * must not be any indication of current receipt of hospice care * no record of recent death in the administrative data * not scheduled for either a screening or diagnostic mammogram within the following 12 weeks from assessment. * not have a personal history of bilateral mastectomy.

Keywords: cancer screening adherence
study to evaluate immune responses in neurologically normal cancer patients

Conditions: Cancer

Summary: the purpose of this study is to study whether immune cells capable of killing tumors that express proteins associated with paraneoplastic neurologic syndrome (pns) can be found in small cell lung cancer and ovarian cancer patients. the presence of these cells may play a role in tumor immunity in these patients. the protocol involves neurological examinations and collection of blood.

see brief description

Eligibility criteria:
inclusion criteria: 1. males and females ages 25 -75 2. if leukapheresis: hepatitis b surface antigen negative if tested\* hepatitis c antibody negative if tested\* hiv antibody negative if tested\* venereal disease reaction level (vdrl) negative if tested\* no known iv drug users hemoglobin \> 8.5 white blood cell count \> 3,800 platelets \> 120,000 international normalized ratio (inr) \< 2 (verified only if clinically indicated) 3. if large blood draw (1/2 to 1 unit) in lieu of leukapheresis: hepatitis b surface antigen negative if tested\* hepatitis c antibody negative if tested\* hiv antibody negative if tested\* vdrl negative if tested\* no known iv drug users hgb \> 10.0 wbc \> 3,800 platelets \> 120,000 inr \< 2 (verified only if clinically indicated) exclusion criteria: no known neurologic disease 2. no known central nervous system (cns) metastasis on clinical exam 3. no chemotherapy within 1 month 4. no new york heart association class iii/iv status 5. no pulmonary disease which limits daily activities 6. no anticoagulation therapy

Keywords: paraneoplastic; autoimmunity;
immune response under immunotherapy in metastatic nsclc: sputum, blood samples and microbioata study

Conditions: Non-squamous Lung Cancer; Metastatic Lung Cancer

Summary: prospective pathophysiological exploratory monocentric study, focusing on adult patients with non-small cell lung cancer (nsclc) : non-squamous type without oncogenic addiction, metastatic, treated with immune checkpoint inhibitors alone or in combination with chemotherapy in front line at the chru de tours, france.

the percentage of patients benefiting from immunotherapy is quite low and their systemic side effects can sometimes be severe. one of the main difficulties is to identify before treatment patients who will respond to immune checkpoint inhibitors. currently, the selection is done in a very large majority of cases on the expression of pd-l1 by the tumor. but this biomarker is not sufficient to identify patients responding or not to immune checkpoint inhibitors. in addition, factors extrinsic to the tumor, to its microenvironment and patient immunity may be involved in the response to immunotherapy such as the microbiota. the investigators therefore assume that the immune response in place during immunotherapy treatment differs according to the profile of patient response to immunotherapy. the main objective of this project is to describe local and systemic anti-tumor immune system of patients responders or not to immune checkpoint inhibitors, but also whether the immunological characterization of sputum could be a reflection of the microenvironment tumor. the secondary objective is to study the intestinal microbiota tract of patients receiving immunotherapy, depending on their consumption of antibiotics, and compare it to the pulmonary microbiota.

Eligibility criteria:
inclusion criteria: * age of 18 years or over * diagnosis of metastatic nsclc (stage iv) adenocarcinoma only * absence of oncogenic addiction (egfr, alk, ros1, ret, met, braf) * treatment with ici anti-pd1 or anti-pdl1 (pembrolizumab or atezolizumab) as 1st line treatment alone or in combination with chemotherapy and/or anti-angiogenic (bevacizumab). * 1st injection of ici, whether or not combined with chemotherapy exclusion criteria: * patient under judicial protection * pregnant or breastfeeding women * nsclc of the epidermal or undifferentiated type * opposition to data processing

Keywords: blood sample sputum microbiota immunotherapy saliva
real-world daptomycin use in chinese icus

Conditions: Daptomycin; Real-world Study; Intensive Care Unit

Summary: analyze the effectiveness and safety of daptomycin(jiangsu hengrui medicine co., ltd) in gram-positive infections in chinese intensive care units by using the real-world data platform, https://rws.scccmqc.com. patients who received at least one dose of daptomycin between 2016 to 2021 are eligible.


Eligibility criteria:
inclusion criteria: * patient who received at least one dose of daptomycin exclusion criteria: * no
tdcs in patients with disorders of consciousness

Conditions: Consciousness Disorder; Transcranial Direct Current Stimulation

Summary: test

neurostimulation techniques such as deep brain stimulation (dbs) and spinal cord stimulation (scs) have been used to treat doc. although these techniques have been shown to increase patient response, there are still some limitations. for example, dbs requires craniotomy and may increase the risk of intracranial hemorrhage and infection. in addition, the complexity and cost of these technologies also limit their potential applications.

Eligibility criteria:
inclusion criteria: patients with doc: vs and mcs (the cause of unification is: traumatic brain injury, the course of more than 1 month, not more than 1 year ; age 18-65; past history without a mental disorder; no previous alcohol or substance abuse; no epilepsy or frequent spontaneous movement; no benzodiazepines; no moderate or severe hydrocephalus, all patients were right handed. exclusion criteria: exclusion of organic heart disease, such as sinus bradycardia, arrhythmia; exclusion of patients with intracranial metal devices, pacemakers or any other device.
the influence of local antibiotic therapy on the outcomes following periodontal regeneration procedures.

Conditions: Periodontitis; Periodontal Diseases

Summary: assessmnet of the influence of local antibiotic therapy on the clinical, radiological, microbiological parameters and the inflammation mediators levels in the gingival crevicular fluid (gcf) following periodontal regeneration procedures in patients with periodontitis.

forty generally healthy adults diagnosed with stage iii periodontitis were randomly divided into two groups. in the test group, srp was performed with the subsequent application of local antibiotics (10% doxycycline) into periodontal pockets at the site of the planned surgical intervention, while in the control group srp was performed alone. two weeks after, on the day of the surgical treatment, the m-mist/mist procedure was performed in both the test and control groups with the use of enamel matrix derivative (emd). clinical examination was performed before and 6 and 12 months after treatment. for radiological measurements rvg was performed. for inflammation mediators levels determination in gcf samples elisa method will be used. for microbiological assessments real time pcr method will be used.

Eligibility criteria:
inclusion criteria: -presence of an intrabony defect, with a pocket depth (pd) ≥ 6 mm and a radiological defect depth of ≥3 mm and width of ≥2 mm; exclusion criteria: * periodontal treatment within 3 months prior to the study; * antibiotic therapy within 3 months prior to the study; * smoking; presence of systemic diseases affecting periodontal healing, i.e.: immunosuppressive diseases, diabetes, osteoporosis, aids, hypertension treated with calcium channel blockers; * use of steroids or other immunosuppressive drugs; * pregnant and breastfeeding women

Keywords: periodontitis periodontal regeneration local antibiotics
safety and effectiveness of extended circumferential decompression for thoracic ossification of posterior longitudinal ligament

Conditions: Indications and Effectiveness for Extended Posterior Circumferential Decompression

Summary: the study was to evaluate the indications, efficiency and safety of the extended posterior circumferential decompression technique for the treatment of thoracic ossification of posterior longitudinal ligament (topll) with dura adhesions or ossification.

the clinical characteristics of patients with topll combined with dura adhesions who underwent extended circumferential decompression in our hospital were retrospectively investigated. topll adhered with dura matter or dura ossification were detected intraoperatively in all the cases. imaging evaluation included the ossification-kyphosis angle and the fixed-segment kyphosis angle. a modified japanese orthopedic association score (joa score) was applied for the evaluation of clinical outcomes.

Eligibility criteria:
inclusion criteria: (1) thoracic myelopathy caused by topll with or without tolf; (2) severe adhesions between dura mater and ossified lesion with or without dura ossification confirmed intraoperatively; (3) extended posterior circumferential decompression was applied; (4) pedicle screw instrumentations were implanted after decompression; (5) follow-up for more than 6 months; (7) complete clinical data. exclusion criteria: (1) spinal deformities; (2) thoracic spine fractures; (3) syringomyelia, spinal tumor, myelitis, etc.; (4) coexisted with cervical spondylosis and lumbar stenosis; (5) post operation of thoracic spinal stenosis; (6) recurrent myelopathy caused by lesions in other levels than the decompressed segments.

Keywords: circumferential decompression thoracic ossification of posterior longitudinal ligament kyphosis neurological outcomes
serum cytokine values in patients with granulomatous mastitis

Conditions: Granulomatous Mastitis

Summary: granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying etiologies, including infectious and non-infectious causes. etiological reasons were examined in various studies, but neither etiology nor definite criteria for diagnosis were found. our aim in this study is to examine the role of cytokines in differentiating the etiology of granulomatous mastitis and using it as a prognostic marker.

granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying aetiology, including infectious and non-infectious causes. this disease can clinically and radiographically mimic breast cancer, which can pose a diagnostic challenge as well as concern during evaluation. a nonspecific inflammatory response, 'granuloma' is defined as necrosis or infiltration of other inflammatory leukocytes, with or without mononuclear phagocyte collection. it is thought to be caused by infectious agents or foreign substances that activate the immune system, leading to granuloma formation. some of the known inflammatory etiologies of granulomatous mastitis are autoimmune diseases such as tuberculosis (most commonly caused by mycobacterium tuberculosis), sarcoidosis, fungal infection and granulomatosis with polyangiitis and giant cell arteritis. these diseases cannot be distinguished clinically, pathologically, and radiographically from idiopathic granulomatous mastitis.in this study, we aimed to investigate il-1β, ifn-α2, ifn-γ, tnf-α, mcp-1 (ccl2), il-6, il-8 (cxcl8), il-10, il-12p70, il-17a, il-18, il-23, il-33 levels in patients with granulomatous mastitis and to evaluate the differences in cytokine levels and its usability as a predictive marker in diagnosis.

Eligibility criteria:
inclusion criteria: * patients with granulomatous mastitis exclusion criteria: * cancer patients * patients with known immunodeficiency * pregnancy * patient diagnosed with tuberculosis

Keywords: mastitis cytokine flow-cytometry
anlotinib hydrochloride capsules combined with penpulimab injection for the treatment of hepatocellular carcinoma at high risk of recurrence.

Conditions: Hepatocellular Carcinoma

Summary: the primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or ablation in hcc patients with high risk of recurrence by assessing recurrence-free survival (rfs).


Eligibility criteria:
inclusion criteria: * age: 18-75 years old; eastern cooperative oncology group performance status (ecog ps) ≤ 1; predicted survival ≥12 weeks. * subjects with hepatocellular carcinoma (hcc) confirmed by histopathology or cytology or who meet the diagnostic criteria for primary liver cancer 2022 or the american association for the study of hepatology (aasld) hepatocellular carcinoma. * subjects who received radical excision or ablation (radio frequency ablation (rfa) or microwave ablation (mwa) only) within 4 to 12 weeks prior to randomization (multiple modalities or combined or multiple treatments are not acceptable). * no major vena portae 3 (vp3) or vena portae 4 (vp4) in the portal vein or any level of vascular invasion in the hepatic vein or inferior vena cava. * no extrahepatic metastasis. * high risk factors for recurrence after radical resection or complete ablation. * complete recovery from surgical resection or ablation within 4 weeks before randomization. exclusion criteria: * known fibrolamellar hcc, sarcomatoid hcc, or mixed cholangiocarcinoma and hcc histology. * evidence of residual, recurrent, or metastatic disease at randomization. * more than one surgical treatment for hepatocellular carcinoma; received more than 1 prophylactic transcatheter arterial chemoembolization (tace) treatment after surgery; or received hepatic artery infusion chemotherapy (haic) therapy after surgery. * previous use of antiangiogenic drugs or pd-1, programmed cell death-ligand 1 (pd-l1) and other related immunotherapy drugs or systemic chemotherapy drugs.
phase ii study dcvac/ovca added to first line carboplatin and paclitaxel newly diagnosed epithelial ovarian carcinoma

Conditions: Ovarian Neoplasms; Ovarian Epithelial Cancer

Summary: the purpose of this study is to determine whether dcvac/ovca added to chemotherapy (carboplatin plus paclitaxel as first line chemotherapy) may result in prolongation of progression free survival (pfs).

the purpose of this study is to determine whether dcvac/ovca added to standard of care chemotherapy (carboplatin plus paclitaxel as first line chemotherapy) may result in prolongation of progression free survival (pfs).

Eligibility criteria:
inclusion criteria: * female aged ≥18 years * patients with newly diagnosed, histologically confirmed, international federation of gynecology and obstetrics (figo) stage iii epithelial ovarian, primary peritoneal or fallopian tube carcinoma (serous, endometrioid or mucinous) who have undergone initial surgery up to 3 weeks before randomization and are selected to receive first line standard of care chemotherapy (optional prolongation to 6 weeks after surgery) * optimally debulked (zero residuum) or maximal residuum \<1cm * eastern cooperative oncology group (ecog) performance status 0,1,2 exclusion criteria: * figo i,ii,iv epithelial ovarian cancer * figo iii clear cells epithelial ovarian cancer * non-epithelial ovarian cancer (ovca), borderline tumors (tumors of low malignant potential) * post-surgery residual disease with lesion(s) \>1cm * prior or current systemic anti-cancer therapy for ovarian cancer \[for example chemotherapy, monoclonal antibody therapy (bevacizumab), tyrosine kinase inhibitor therapy, vascular endothelial growth factor (vegf) therapy or hormonal therapy\] * previous or concurrent radiotherapy to the abdomen and pelvis * malignancy other than epithelial ovarian cancer, except those that have been in clinical remission (cr) for a minimum of 3 years, and except carcinoma in-situ of the cervix or non-melanoma skin carcinomas * patient co-morbidities:human immunodeficiency virus (hiv) positive, human t-lymphotropic virus (htlv) positive, active hepatitis b (hbv), active hepatitis c (hcv), active syphilis * evidence of active bacterial, viral or fungal infection requiring systemic treatment * clinically significant cardiovascular disease including: symptomatic congestive heart failure unstable angina pectoris serious cardiac arrhythmia requiring medication uncontrolled hypertension myocardial infarction or ventricular arrhythmia or stroke within a 6 month period before inclusion, ejection fraction (ef) \< 40 percent or serious cardiac conduction system disorders, if a pacemaker is not present

Keywords: serous endometrioid mucinous epithelial ovarian cancer
sequencing in inflammatory bowel diseases (ibd) therapy: "the latium net".

Conditions: IBD (Inflammatory Bowel Disease)

Summary: patients with ibd, both uc and cd, who fulfil the inclusion and exclusion criteria will be included consecutively: * retrospective cohort patients treated with ibd from january 2015 to june 2024 will be included. * prospective cohort consecutive patients with ibd who are starting, from clinical practice, new biological/small molecule therapies, failure (already exposed) to a mechanism of action (for anti tnf-alpha, more than one molecule is allowed), and who belong to the lazio regional health system. eligible subjects will be identified among patients belonging to the ibd unit of the digestive diseases centre (cemad) of the foundation and to all the other ibd units of all the centres specified in annex 1. based on the number of patients referred to the clinics, we estimate 112 patients per month, the time for recruitment is 24 months. potential study participants will receive oral and written information about the study. patients who agree to participate in the study will be asked to sign a written informed consent according to gcp.

multicenter, ambispectic observational study with drug

Eligibility criteria:
inclusion criteria: 1. age 18 to 70 years 2. patients with a previous diagnosis of cd or uc at least 3 months before baseline. 3. patients who have already failed at least one advanced (biological or small molecule) therapy for ibd and who have experienced failure to at least one mechanism of action (failure is defined as primary failure, secondary failure, or intolerance). 4. patients who have already started a new advanced therapy for ibd based on clinical practice indication (primary loss of response, secondary loss of response, intolerance to the previous drug) since at least 1 week and up to 8 weeks after starting it. 5. written informed consent certifying the willingness of the subject to participate to the study. exclusion criteria: 1. age \< 18 years. 2. patients with diagnosis of indeterminate colitis. 3. patients naive to advanced (biological or small molecule) therapy for ibd. 4. refusal to sign written informed consent certifying the willingness of the subject to participate to the study.